Publications by authors named "Clemency Stephenson"
Article Synopsis
- * Out of those tested, 118 had COVID-19, with 94 showing symptoms and only 2 fatalities, revealing high levels of S1-reactive and neutralizing antibodies against the virus.
- * Immune responses varied, particularly with hematological cancer patients showing unique challenges but still managing clinical recovery, highlighting the need for more research on immune durability against different SARS-CoV-2 variants.
Article Synopsis
- The CAPTURE study evaluated COVID-19 immunity in 585 cancer patients after receiving two doses of either BNT162b2 or AZD1222 vaccines, revealing seroconversion rates of 85% for those with solid tumors and 59% for those with hematological malignancies.
- Patients with hematological cancers had significantly lower levels of detectable neutralizing antibodies (NAbT) against SARS-CoV-2 variants compared to those with solid tumors and healthy individuals.
- Previous COVID-19 infections increased NAb responses, particularly against variants, but treatment with anti-CD20 medications correlated with undetectable NAbT, highlighting important considerations for cancer patient management during the pandemic.
CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively.
View Article and Find Full Text PDFArticle Synopsis
- * A high percentage (83%) of patients developed S1-reactive antibodies, but neutralizing antibody levels against virus variants (Alpha, Beta, Delta) were significantly lower, despite stable levels over time.
- * The study indicated that while most patients had detectable SARS-CoV-2-specific T cells and antibody responses, those with blood cancers exhibited weaker immune responses linked to their specific conditions and treatments, yet they still showed some compensatory immune activity.
Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n = 1234).
View Article and Find Full Text PDFOne out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.
View Article and Find Full Text PDFWe conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs.
View Article and Find Full Text PDFAims: Old age and diabetes are risk factors that often coexist increasing the vulnerability of the heart to the lethal effects of ischaemia-reperfusion injury (IRI). However, to our knowledge, no investigations have examined IRI and cardioprotective signalling in animal models bearing these co-morbidities concomitantly. The ability of the heart to recover following IRI is greatly dependent on its innate cardioprotective potential, in which a central role is played by Akt.
View Article and Find Full Text PDF